TDSGF (Telo Genomics) Tariff Resilience Score: 5/10 (As of Jul. 02, 2026)


What is Telo Genomics Tariff Resilience Score?

Telo Genomics TDSGF Tariff Resilience Score is 5 as of Jul. 02, 2026. The stock has 2 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Telo Genomics ranks better than 75.35% on this metric.

Telo Genomics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Telo Genomics has Telo Genomics relies on international suppliers for specialized components, making it moderately vulnerable. Limited pricing power and niche market focus increase risk.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Telo Genomics might have Average Resilient.

Telo Genomics  (OTCPK:TDSGF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Telo Genomics Tariff Resilience Score Related Terms

TDSGF vs TMO, DHR, IDXX: Tariff Resilience Score Comparison

For the Diagnostics & Research subindustry, Telo Genomics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telo Genomics Tariff Resilience Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 5 mean?
Telo Genomics (TDSGF) has a Tariff Resilience Score of 5 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Telo Genomics ranks #53 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 24.7%.
Is Telo Genomics' Tariff Resilience Score too high?
Telo Genomics' current Tariff Resilience Score is 5. Based on the distribution chart, Telo Genomics ranks #53 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Telo Genomics' Tariff Resilience Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Telo Genomics ranks #53 out of 215 companies for Tariff Resilience Score. This places Telo Genomics in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Diagnostics & Research company?
A good Tariff Resilience Score depends on the Medical Diagnostics & Research industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Telo Genomics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telo Genomics stock overvalued right now?
Telo Genomics (TDSGF) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Telo Genomics (TDSGF), the current Tariff Resilience Score is 5 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Telo Genomics Business Description

Other Exchanges 3D0A:GermanyTELO:Canada
Address 2255 York Avenue, Suite 203, Vancouver, BC, CAN, V6K 1C5
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.